Insider Trading Alert - ENTA, KMG And ENTG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 12, 2015, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $4,322,819.24.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Or Yat Sun, who is Chief Scientific Officer at Enanta Pharmaceuticals, sold 8,000 shares at $36.13 on May 12, 2015. Following this transaction, the Chief Scientific Officer owned 230,231 shares meaning that the stake was reduced by 3.36% with the 8,000-share transaction.

The shares most recently traded at $36.22, up $0.09, or 0.25% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 70,500

The average volume for Enanta Pharmaceuticals has been 315,900 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $666.7 million and is part of the health care sector and drugs industry. Shares are down 29.85% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 5.9. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

KMG Chemicals (KMG) - FREE Research Report

Hatcher David L, who is 10% Owner at KMG Chemicals, sold 3,000 shares at $28.48 on May 12, 2015. Following this transaction, the 10% Owner owned 2.0 million shares meaning that the stake was reduced by 0.15% with the 3,000-share transaction.

The shares most recently traded at $29.78, up $1.30, or 4.38% since the insider transaction. Historical insider transactions for KMG Chemicals go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 25,500
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 39,500
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 39,500

The average volume for KMG Chemicals has been 69,000 shares per day over the past 30 days. KMG Chemicals has a market cap of $328.6 million and is part of the basic materials sector and chemicals industry. Shares are up 40.65% year-to-date as of the close of trading on Tuesday.

KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture, formulation, and distribution of specialty chemicals in the United States, Mexico, Canada, Europe, Israel, and Singapore. It operates in two segments, Electronic Chemicals and Wood Treating Chemicals. The stock currently has a dividend yield of 0.43%. The company has a P/E ratio of 46.9. Currently, there is 1 analyst who rates KMG Chemicals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMG - FREE

TheStreet Quant Ratings rates KMG Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full KMG Chemicals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Entegris (ENTG) - FREE Research Report

Burns Robert Nicholas, who is Director at Entegris, sold 7,475 shares at $13.42 on May 12, 2015. Following this transaction, the Director owned 32,552 shares meaning that the stake was reduced by 18.67% with the 7,475-share transaction.

The shares most recently traded at $13.66, up $0.24, or 1.74% since the insider transaction. Historical insider transactions for Entegris go as follows:

  • 4-Week # shares bought: 123,600
  • 4-Week # shares sold: 4,554
  • 12-Week # shares bought: 123,600
  • 12-Week # shares sold: 8,318
  • 24-Week # shares bought: 123,600
  • 24-Week # shares sold: 12,818

The average volume for Entegris has been 690,700 shares per day over the past 30 days. Entegris has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are up 1.06% year-to-date as of the close of trading on Tuesday.

Entegris, Inc. manufactures and sells a range of products and services for purifying, protecting, and transporting the critical materials used in processing and manufacturing in the microelectronics and other high-technology industries worldwide. The company has a P/E ratio of 190.7. Currently, there are 2 analysts who rate Entegris a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTG - FREE

TheStreet Quant Ratings rates Entegris as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Entegris Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%